Bayer Pharma AG et al v. Lupin Limited et al
| Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc. |
| Lupin Limited and Lupin Pharmaceuticals, Inc. |
| 1:2024cv00138 |
| February 2, 2024 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on April 1, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 13
STIPULATION and Order Regarding Consolidation and Schedule - by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek)
|
| Filing 12 NOTICE of Appearance by Megan C. Haney on behalf of Lupin Limited, Lupin Pharmaceuticals, Inc. (Haney, Megan) |
| Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited for Lupin Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc. filed by Lupin Limited, Lupin Pharmaceuticals, Inc.. (Haney, Megan) |
| Filing 10 ANSWER to #1 Complaint, Affirmative Defenses, and COUNTERCLAIMS against All Plaintiffs, by Lupin Pharmaceuticals, Inc., Lupin Limited.(Haney, Megan) Modified on 3/19/2024 (nms). |
| CORRECTING ENTRY: The Answer filed at D.I. 10, the 7.1 Disclosure statement at D.I. 11, and Notice of Appearance filed at D.I. 12 all filed on 3/19/2024, have been removed from the docket. This case is a member case to MDL 21-3017-RGA and therefore all filings require in the case caption reference to the MDL and the underlying member case. Counsel is to amend all documents and refile accordingly. (nms) |
| Filing 9 SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Lupin Pharmaceuticals, Inc. served on 2/27/2024, answer due 3/19/2024. (Fahnestock, Derek) |
| Filing 8 SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Lupin Limited served on 2/27/2024, answer due 3/19/2024. (Fahnestock, Derek) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 7 Summons Issued as to Lupin Limited on 2/2/2024; Lupin Pharmaceuticals, Inc. on 2/2/2024. (Attachments: #1 Summons Issued)(apk) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc.. (apk) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer AG, Bayer Pharma AG. (apk) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (apk) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/22/2023. Date of Expiration of Patent: SEE ANDA FORM. (apk) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) |
| Filing 1 COMPLAINT filed against Lupin Limited, Lupin Pharmaceuticals, Inc. ( Filing fee $ 405, receipt number ADEDC-4329152.) - filed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(apk) |
| Remark: MDL Panel has been Notified (apk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
